Neose and BioGeneriX in commercial agreement for second GlycoPEGylated next generation protein
US company Neose Technologies and BioGeneriX, part of the European generics producer ratiopharm Group, have entered into a research, license and option agreement to use Neose's proprietary GlycoPEGylation technology to develop a long-acting, next-generation version of a currently marketed therapeutic protein.
US company Neose Technologies and BioGeneriX, part of the European generics producer ratiopharm Group, have entered into a research, license and option agreement to use Neose's proprietary GlycoPEGylation technology to develop a long-acting, next-generation version of a currently marketed therapeutic protein.
Neose and BioGeneriX had previously announced a supply and option agreement for this protein.
Under the commercial agreement, Neose will receive further upfront and research payments, and could receive milestone payments of up to US$61.5m, as well as royalties on product sales. BioGeneriX has the right to an exclusive, worldwide licence to use Neose's GlycoPEGylation technology to develop and commercialise a long-acting, next generation version of the undisclosed therapeutic protein.
Neose's GlycoPEGylation technology can extend and customise protein half- life by uniquely linking various size polyethylene glycol polymers to glycans that are remote from the protein's active site, thereby preserving activity. Proteins that have not benefited from traditional chemical pegylation may benefit from GlycoPEGylation.